Amniotic Membrane Grafts to Reduce Pterygium Recurrence

Ronald Rosen, MD

Purpose: To demonstrate the long-term outcome of pterygium surgery with adjunctive amniotic membrane transplantation (AMT) and intraoperative mitomycin C (MMC) in a large case series.

Methods: Medical records were retrieved for this noncomparative retrospective study of all patients who had pterygium excision with adjunctive AMT and intraoperative MMC, from October 2010 to June 2016 with at least 6 months of follow-up.

Results: There were a total of 556 eyes of 535 patients (291 males and 244 females) with average age of 51.9 ± 13 years who had pterygium excision (527 primary and 29 recurrent). For an average follow-up period of 17.3 ± 0.8 months (range 6–74 months), corneal recurrence occurred in 20 eyes (3.6%) and conjunctival recurrence in 12 (2.2%) in a total of 32 eyes (5.8%). Eleven eyes (2%) underwent reoperation. Other complications included granuloma (0.5%), diplopia (1.1%), and steroid-induced ocular hypertension (4.3%).

Conclusions: Adjunctive use of AMT and short exposure of MMC can reduce recurrence after pterygium surgery. The procedure is less tedious and less time consuming, resulting in early recovery while saving the conjunctiva for future surgeries.

Key Words: amniotic membrane, fibrin glue, mitomycin C, pterygium, recurrence

(Cornea 2018;37:189–193)

Pterygium is a wing-shaped superficial overgrowth on the ocular surface, which is characterized by inflammation, fibrovascular conjunctival proliferation, and invasion of the corneal surface.1–3 It is presumably due to ultraviolet-induced damage to the limbal stem cells4,5 and hence considered as focal limbal stem cell deficiency.5 Surgical excision is indicated for either optical or cosmetic reasons. In the former, visual disturbances are caused by irregular astigmatism, blocking of the visual axis, or restricted ocular motility.

The most daunting challenge of pterygium surgery is the high incidence of recurrence, as high as 88% with simple excision involving an uncovered bare sclera. Surgical techniques in more recent years, in which scleral defects are covered with conjunctival autograft or cryopreserved amniotic membrane (CAM) with or without mitomycin C (MMC), have resulted in much better outcomes, with less than 10% recurrence rates and minimal complications postoperatively.6–8 However, some debate still continues regarding which graft offers the better outcome.9–11

The purpose of this retrospective analysis is to provide compelling long-term evidence that CAM grafts, combined with short exposure to MMC, can reduce recurrence and complications after pterygium surgery. To the best of our knowledge, this is the largest sample size reported with a long-term follow-up.

METHODS

Study Design and Participants
The study was approved and supported by a grant from the Kaiser Permanente Southern California Regional Research Committee and was conducted in accordance with the Health Insurance Portability and Accountability Act (HIPAA) and Declaration of Helsinki. In this noncomparative retrospective study, the medical records of all patients who had pterygium excision with adjunctive amniotic membrane transplantation (AMT) and MMC by the same surgeon (R.R.) from October 2010 to June 2016, at the Southern California Kaiser Permanente Medical Center, Panorama City, were reviewed. A total of 535 patients were identified during the study interval, and all of them had completed at least 6 months of follow-up. Tables 1–3 summarize the data collected regarding demographic characteristics, type of pterygium (primary or recurrent), surgical technique, postoperative complications, pterygium recurrence, and reoperation.

Surgical Technique
Ocular surface inflammation, dryness, and exposure were addressed before surgery (Fig. 1). Tetracaine hydrochloride (Tetravisce 0.5%, Ocusoft) was applied as preoperative anesthesia. The eye was draped, lid speculum placed, and superior and inferior limbal 6-0 Vicryl (Ethicon, Somerville, NJ) traction sutures were inserted to retract the globe...
temporally. This offered better exposure and juxtaposition, to help close the conjunctival–Tenon gap. Subconjunctival 2% lidocaine with 1:100,000 epinephrine (lidocaine, Accutome) was then injected under the pterygium. The pterygium was excised with sharp Westcott scissors and avulsed off the cornea. The bipolar cautery was then used for moderate hemostasis and the Bowman corneal layer. Tenon vascular tissue was excised. A motorized burr was used to further dissect pterygium off the sclera. The CAM (AmnioGraft; Bio-Tissue, Miami, FL) was then injected under the pterygium. The pterygium was cut in an elliptical shape at least 2 mm over the defect size, placed with the sticky stromal side down, and pushed toward the conjunctival–Tenon gap before gluing. A small amount of fibrin glue (Tisseel; Baxter, Glendale, CA) was injected consecutively under the graft, then “squeegied” across the graft with a muscle hook toward the cornea, taking care to maintain the graft position. The edge toward the cornea was trimmed with Vannas scissors so as not to cover the pupil margin. Then, the gap edge and the graft corneal edge were reglued with dexamethasone were injected, and a tiny layer of additional glue. Subconjunctival cefazolin and the reduction of the time of MMC exposure from 60 to 90 seconds for the first 179 cases to 20 to 30 seconds for the remaining cases because 3 (0.5%) eyes of the former developed scleral thinning. No scleral thinning was encountered thereafter. The second modification was to discontinue

### TABLE 1. Study Population Baseline Characteristics and Results by Sex

|                          | Female | Male | Total | P  |
|--------------------------|--------|------|-------|----|
|                          | n = 254 | n = 302 | N = 556 |
| Overview of pterygium surgeries, n (%) | 17 (6.7) | 15 (5) | 32 (5.8) | 0.384 |
| Recurrent pterygium       | 9 (3.5) | 11 (3.6) | 20 (3.6) | 0.3368 |
| Corneal recurrence        | 8 (3.1) | 4 (1.3) | 12 (2.2) | 0.3368 |
| Conjunctival recurrence   | 4 (1.6) | 7 (2.3) | 11 (2) | 0.5308 |
| Same eye reoperation*     | 20 (7.9) | 22 (7.3) | 42 (7.6) | 0.7934 |
| Bilateral eyes†           | 4 (1.6) | 11 (3.6) | 15 (2.7) | 0.1339 |
| Double pterygium with a double graft | 1 (0.4) | 2 (0.7) | 3 (0.5) | 0.6668 |
| Postoperative complications, n (%) | 1 (3.1) | 16 (5.3) | 24 (4.3) | 0.2144 |
| Conjunctival granuloma    | 3 (1.2) | 3 (1) | 6 (1.1) | 0.831 |
| Diplopia                  | 8 (3.1) | 16 (5.3) | 24 (4.3) | 0.2144 |
| Ocular hypertension      | 2 (0.8) | 3 (1) | 5 (0.9) | 0.7977 |
| Perioperative treatment,‡ n (%) | 155 (61) | 189 (62.6) | 344 (61.9) | 0.7061 |
| Pred Forte                | 2 (0.8) | 3 (1) | 5 (0.9) | 0.7977 |
| Demographic characteristics | 51.5 (13.22) | 52.3 (12.75) | 51.9 (12.96) | 0.4737 |
| Age at surgery, yrs, mean (SD) | 51.5 (13.22) | 52.3 (12.75) | 51.9 (12.96) | 0.4737 |
| Race/ethnicity, n (%)     | 13 (5.1) | 18 (6) | 31 (5.6) | 0.3634 |
| White, non-Hispanic       | 1 (0.4) | 3 (1) | 4 (0.7) | 0.7792 |
| Hispanic                  | 218 (85.8) | 264 (87.4) | 482 (86.7) | 0.5424 |
| Asian, non-Hispanic       | 20 (7.9) | 17 (5.6) | 37 (6.7) | 0.7792 |
| Other, non-Hispanic       | 2 (0.8) | 0 (0) | 2 (0.4) | 0.0002 |

*The number of duplicate eye reoperations is included in the number of recurrences.†Both left and right eyes.‡Within 1 week of surgery.

---

### TABLE 2. Study Population Baseline Characteristics and Results by Age (<50 Years vs. ≥50 Years)

|                          | <50 yrs | ≥50 yrs | Total | P  |
|--------------------------|---------|---------|-------|----|
|                          | n = 257 | n = 299 | N = 556 |
| Overview of pterygium surgeries, n (%) | 22 (8.6) | 10 (3.3) | 32 (5.8) | 0.0085 |
| Recurrent pterygium       | 14 (5.4) | 6 (2.0) | 20 (3.6) | 0.0307 |
| Corneal recurrence        | 8 (3.1) | 4 (1.3) | 12 (2.2) | 0.0307 |
| Conjunctival recurrence   | 9 (3.5) | 2 (0.7) | 11 (2) | 0.5038 |
| Same eye reoperation*     | 22 (8.6) | 20 (6.7) | 42 (7.6) | 0.4501 |
| Bilateral eyes†           | 7 (2.7) | 8 (2.7) | 15 (2.7) | 0.9721 |
| Double pterygium with a double graft | 3 (1.2) | 0 (0) | 3 (0.5) | 0.061 |
| Postoperative complications, n (%) | 3 (1.2) | 4 (1.3) | 6 (1.1) | 0.5243 |
| Conjunctival granuloma    | 2 (0.8) | 4 (1.3) | 6 (1.1) | 0.5243 |
| Diplopia                  | 4 (1.6) | 20 (6.7) | 24 (4.3) | 0.003 |
| Ocular hypertension      | 2 (0.8) | 3 (1) | 5 (0.9) | 0.7729 |
| Perioperative treatment,‡ n (%) | 174 (67.7) | 170 (56.9) | 344 (61.9) | 0.0086 |
| Pred Forte                | 2 (0.8) | 3 (1) | 5 (0.9) | 0.7729 |
| Demographic characteristics | 40.7 (6.80) | 61.6 (8.40) | 51.9 (12.96) | <0.0001 |
| Age at surgery, yrs, mean (SD) | 40.7 (6.80) | 61.6 (8.40) | 51.9 (12.96) | <0.0001 |
| Patient sex, n (%)        | 124 (48.2) | 130 (43.5) | 254 (45.7) | 0.2602 |
| Female                    | 133 (51.8) | 169 (56.5) | 302 (54.3) | 0.2602 |
| Male                      | 11 (4.3) | 20 (6.7) | 31 (5.6) | 0.0002 |
| Race/ethnicity, n (%)     | 238 (92.6) | 244 (81.6) | 482 (86.7) | 0.0002 |
| White, non-Hispanic       | 1 (0.4) | 3 (1) | 4 (0.7) | 0.0002 |
| Black, non-Hispanic       | 11 (4.3) | 20 (6.7) | 31 (5.6) | 0.0002 |
| Hispanic                  | 238 (92.6) | 244 (81.6) | 482 (86.7) | 0.0002 |
| Asian, non-Hispanic       | 5 (1.9) | 32 (10.7) | 37 (6.7) | 0.0002 |
| Other, non-Hispanic       | 2 (0.8) | 0 (0) | 2 (0.4) | 0.0002 |

*The number of duplicate eye reoperations is included in the number of recurrences.†Both left and right eyes.‡Within 1 week of surgery.
TABLE 3. Study Population Baseline Characteristics and Results by Age (<40 Years vs. ≥40 Years)

|                               | <40 yrs | ≥40 yrs | Total | P    |
|-------------------------------|---------|---------|-------|------|
|                               | n = 94  | n = 462 | N = 556 |      |
| Overview of pterygium         |         |         |       |      |
| surgeries, n (%)              |         |         |       |      |
| Recurrent pterygium           | 5 (5.3) | 27 (5.8)| 32 (5.8) | 0.8421 |
| Corneal recurrence            | 5 (5.3) | 15 (3.2)| 20 (3.6) | 0.1849 |
| Conjunctival recurrence       | 0 (0)   | 12 (2.6)| 12 (2.2) | 0.1849 |
| Same eye reoperation*         | 4 (4.3) | 7 (1.5) | 11 (2) | 0.082 |
| Bilateral eyes†               | 14 (14.9)| 28 (6.1)| 42 (7.6)| 0.0031 |
| Double pterygium with a double graft | 2 (2.1) | 13 (2.8)| 15 (2.7) | 0.7082 |
| Postoperative complications, n (%)  |         |         |       |      |
| Conjunctival granuloma        | 2 (2.1) | 1 (0.2)| 3 (0.5) | 0.0211 |
| Diplopia                      | 0 (0)   | 6 (1.3)| 6 (1.1) | 0.2666 |
| Ocular hypertension           | 2 (2.1) | 22 (4.8)| 24 (4.3) | 0.252 |
| Perioperative treatment‡, n (%) |         |         |       |      |
| Pred Forte                    | 62 (66) | 282 (61)| 344 (61.9)| 0.3708 |
| Flurometholone                | 0 (0)   | 5 (1.1)| 5 (0.9) | 0.311 |
| Demographic characteristics   |         |         |       |      |
| Age at surgery, yrs, mean (SD) | 33.3 (5.03)| 55.7 (10.56)| 51.9 (12.96)| <0.0001 |
| Patient sex, n (%)            |         |         |       |      |
| Female                        | 45 (47.9)| 209 (45.2)| 254 (45.7)| 0.6402 |
| Male                          | 49 (52.1)| 253 (54.8)| 302 (54.3)| 0.1023 |
| Race/ethnicity, n (%)         |         |         |       |      |
| White, non-Hispanic           | 4 (4.3) | 27 (5.8)| 31 (5.6) |         |
| Black, non-Hispanic           | 0 (0)   | 4 (0.9)| 4 (0.7) |         |
| Hispanic                      | 89 (94.7)| 393 (85.1)| 482 (86.7)|         |
| Asian, non-Hispanic           | 1 (1.1) | 36 (7.8)| 37 (6.7) |         |
| Other, non-Hispanic           | 0 (0)   | 2 (0.4)| 2 (0.4) |         |

*The number of duplicate eye reoperations is included in the number of recurrences.
†Both left and right eyes.
‡Within 1 week of surgery.

Vicryl closure of the conjunctival–Tenon gap because the first 14 eyes developed exuberant postoperative conjunctival injection, which was reversed in all 14 eyes, with the use of postoperative prednisolone acetate drops. The remaining 542 eyes (97.5%) underwent exclusively nonsutured gap closure with the cautery and fibrin glue. The AM was pushed up to help secure the gap and mechanically block regrowth.

Postoperative Care

Postoperative treatment included topical prednisolone 6 times daily for 2 months in tapering dosage, and a quinolone antibiotic was used 4 times per day for 1 week. Patients were examined 1 day, 1 week, 1 month, 3 months, 6 months postoperatively, and as needed thereafter. Complications such as pyogenic granuloma, inclusion cysts, epithelial defects, and dellen formation were recorded. Recurrence was defined as conjunctival if fibrovascular regrowth was limited to the conjunctiva and as corneal if tissue growth extended to the cornea across the limbus.12

RESULTS

There were a total of 535 patients [291 males and 244 females; age (mean ± SD) 51.9 ± 13 years] who underwent pterygium excision with combined MMC and AMT. From the 535 patients, there were a total of 556 eyes, which included 527 (94.8%) eyes with primary pterygium and 29 (5.2%) eyes with recurrent pterygium. Surgery was uneventful in all cases. No dislodgement of AM followed application of fibrin glue without sutures.

For the average maximum follow-up period of 17.3 ± 0.8 months (range 6–74), recurrence occurred in 32 eyes (5.8%), of which 12 eyes (2.2%) had conjunctival recurrence and 20 eyes (3.6%) had corneal recurrence. Eleven eyes that experienced corneal recurrence (2%) underwent reoperation; however, the eyes with conjunctival recurrence did not require surgery. There was no statistically significant difference in recurrence rates by sex (Table 1); however, the recurrent cases were predominantly in patients younger than 50 years (Table 2). The likelihood of pterygia occurring in both eyes was more frequent in younger age groups. Fourteen of the 94 pterygium patients younger than 40 years had pterygia in both eyes (Table 3), which was statistically significant (P = 0.003). Because the majority of the study population was of Hispanic origin, no significant conclusions could be derived regarding the ethnic background.

Other postoperative complications include conjunctival granuloma (0.5%), diplopia (1.1%), and ocular hypertension (4.3%). Ocular hypertension was primarily attributable to postoperative steroid use and was successfully managed with a combination of antihypertensive drops and a switch from prednisolone acetate to fluorometholone steroid drops. Ocular hypertension was more likely to occur in patients older than 50 years. Three (0.5%) eyes developed scleral melting when MMC was used for 60 to 90 seconds. However, no scleral thinning was encountered after reducing the exposure time to 20 to 30 seconds. Suture-related conjunctival vascularization was noted in 14 eyes (2.5%), which was resolved with postoperative prednisolone acetate drops. This vascularization was not observed in the remaining cases after elimination of the sutures. No graft dehiscence after gluing was observed in any of the 556 eyes over the 6 years of the study.

DISCUSSION

Ocular surface inflammation plays an important role in pterygium growth and recurrence. Clinical recognition of causes leading to inflammation and appropriate therapies should be regarded as an adjunctive measure in pterygium management. In this study, we achieved a considerably low
recurrence rate (3.6%) by reducing surgical manipulation during pterygium excision, reducing MMC exposure time, using a CAM graft, and using fibrin glue in lieu of sutures. With further close follow-up, we were able to eliminate the risk of postoperative inflammation.

This study provides several reasons to take a fresh look at pterygium surgical options. The most important reason is the large sample size. In addition, the amniotic membrane (AM) graft technique used in this study is straightforward and consistent throughout the entire study duration. It is also potentially an easier and shorter procedure than the alternatives because the technique obviates the need for preparing a conjunctival autograft of sufficient quality and thinness for optimal grafting after removal of the Tenon layer. AM stromal matrix has been found to be effective in suppressing the expression of TGF-β signaling and myofibroblast transformation of normal ocular surface fibroblasts13 and pterygium body fibroblasts.14 This finding supports the idea that CAM can be used to substitute conjunctival autografts in pterygium surgery.15–19 In fact, Ma et al18 retrospectively evaluated the efficacy and safety of AMT compared with conjunctival autograft and topical 0.02% MMC, after excision of primary pterygium [AM (80), conjunctival autograft (56), and MMC (54)]. There was no significant difference in recurrence rates (AMT = 3.8%, conjunctival autograft = 5.4%, and MMC = 3.7%) among these 3 groups. Although the recurrence rates are comparable in the literature, the AMT procedure is less tedious and less time consuming, while also saving the conjunctiva, especially if it is needed for future glaucoma surgery.

The recurrence rate has also been shown to be correlated with the preoperative pterygium morphology, surgical technique, and age, of which the latter was also confirmed in this study.6,9 Recently, ocular Demodex infestation was also identified as an overlooked risk factor for pterygium recurrence, presumably by perpetuating chronic inflammation mediated by Th17 lymphocytes. Therefore, control of inflammation incited by ocular demodicosis before and after surgery is also important for reducing recurrence and should be considered as a strategy in managing pterygium growth and recurrence.20

The surgical technique is probably the single most important factor influencing recurrence. In a prospective study, Prabhasawat et al16 first reported a recurrence rate of 10.9% in primary pterygium (n = 54) after excision and AMT. Solomon et al17 subsequently modified the technique of AMT and achieved a low recurrence rate of 3% in 33 cases of primary pterygium. Another surgical parameter is the use of MMC. Amano et al21 showed a statistically significant reduction in the recurrence rate when using intraoperative 0.04% MMC (8.7%) instead of β-irradiation (23%). Furthermore, reducing the MMC concentration and exposure time can effectively reduce recurrence while minimizing side effects. In this study, an exposure time of 20 to 30 seconds was effective and without the previously noticed complications of scleral thinning.18,22 To further reduce such a complication, MMC was applied over the truncated fibrovascular tissue, in the gap between the conjunctival edge and the underlying Tenon layer. This approach reduces MMC dosage and avoids overspill to the...
entire ocular surface. Another key step is to seal the gap between the conjunctiva and Tenon using fibrin glue and advance the AM to create a stronger barrier against further recurrence.23

Finally, long-term postoperative steroid use, which is essential for postoperative graft maintenance, will benefit from future enhancement of antiinflammatory effects and further reduction of side effects. Secondary steroid-induced ocular hypertension can hopefully be eradicated in the future without compromising steroid potency.

In conclusion, this study clearly shows that CAM imparts remarkable resilience against further regrowth. Coupled with short exposure to MMC, CAM should be considered an optimal choice for pterygium surgery, and the surgeon can confidently quote low recurrence statistics to his or her patients. Once mastered, the procedural time of this surgical option is potentially shorter, and it is technically easier to perform than conjunctival autografting.

REFERENCES
1. Dushku N, John MK, Schultz GS, et al. Pterygia pathogenesis: corneal invasion by matrix metalloproteinase expressing altered limbal epithelial basal cells. Arch Ophthalmol. 2001;119:695–706.
2. Dushku N, Reid TW. Immunohistochemical evidence that human pterygia originate from an invasion of vimentin-expressing altered limbal epithelial basal cells. Curr Eye Res. 1994;13:473–481.
3. Dushku N, Reid TW. p53 expression in altered limbal basal cells of pingueculae, pterygia, and limbal tumors. Curr Eye Res. 1997;16:1179–1192.
4. Tan DTH, Lim ASM, Goh HS, et al. Abnormal expression of the p53 tumor suppressor gene in the conjunctiva of patients with pterygium. Am J Ophthalmol. 1997;123:404–405.
5. Kwork LS, Coroneo MT. A model for pterygium formation. Cornea. 1994;13:219–224.
6. Tan DTH, Chee SP, Dear KBG, et al. Effect of pterygium morphology on pterygium recurrence in a controlled trial comparing conjunctival autografting with bare sclera excision. Arch Ophthalmol. 1997;115:1235–1240.
7. Wong VA, Law FC. Use of mitomycin C with conjunctival autograft in pterygium surgery in Asian-Canadians. Ophthalmology. 1999;106:1512–1515.
8. Al Fayez MF. Limbal versus conjunctival autograft transplantation for advanced and recurrent pterygium. Ophthalmology. 2002;109:1752–1755.
9. Lewallen S. A randomized trial of conjunctival autografting for pterygium in the tropics. Ophthalmology. 1989;96:1612–1614.
10. McLean C. Pterygium excision with conjunctival autografting. Br J Ophthalmol. 1994;78:421.
11. Ti SE, Chee SP, Dear KB, et al. Analysis of variation in success rates in conjunctival autografting for primary and recurrent pterygium. Br J Ophthalmol. 2000;84:385–389.
12. Liu J, Fu Y, Xu Y, et al. New grading system to improve the surgical outcome of multicentric pterygia. Arch Ophthalmol. 2012;130:39–49.
13. Tseng SC, Li DQ, Ma X. Suppression of transforming growth factor-beta isoforms, TGF-beta receptor type II, and myofibroblast differentiation in cultured human corneal and limbal fibroblasts by amniotic membrane matrix. J Cell Physiol. 1999;179:325–335.
14. Lee SB, Li DQ, Tan DT, et al. Suppression of TGF-beta signaling in both normal conjunctival fibroblasts and pterygial body fibroblasts by amniotic membrane. Curr Eye Res. 2000;20:325–334.
15. Shimazaki J, Shinozaki N, Tsubota K. Transplantation of amniotic membrane and limbal autograft for patients with recurrent pterygium associated with symblepharon. Br J Ophthalmol. 1998;82:235–240.
16. Prabhasawat P, Barton K, Burkett G, et al. Comparison of conjunctival autografts, amniotic membrane grafts, and primary closure for pterygium excision. Ophthalmology. 1997;104:974–985.
17. Solomon A, Pires RTF, Tseng SCG. Amniotic membrane transplantation after extensive removal of primary and recurrent pterygium. Ophthalmology. 2001;108:449–460.
18. Ma DHK, See LC, Liao SB, et al. Amniotic membrane graft for primary pterygium: comparison with conjunctival autograft and topical mitomycin C treatment. Br J Ophthalmol. 2000;84:973–978.
19. Shimazaki J, Kosaka K, Shimura S, et al. Amniotic membrane transplantation with conjunctival autograft for recurrent pterygium. Ophthalmology. 2003;110:119–124.
20. Huang Y, He H, Sheh H, et al. Ocular demodicosis as a risk factor of pterygium recurrence. Ophthalmology. 2013;120:1341–1347.
21. Amano S, Motoyama Y, Oshika T, et al. Comparative study of intraoperative mitomycin C and beta irradiation in pterygium surgery. Br J Ophthalmol. 2000;84:618–621.
22. Sharma A, Gupta A, Ram J, et al. Low-dose intraoperative mitomycin-C versus conjunctival autograft in primary pterygium surgery: long term follow-up. Ophthalmic Surg Lasers. 2000;31:301–307.
23. Zhao D, Yin HY, Cheng A, et al. Sealing of the gap between the conjunctiva and Tenon capsule to improve symblepharon surgery. Am J Ophthalmol. 2015;160:438–446.e1.